Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 3/20 | 0.37 |
| ▸ | ELOC | Q15369 | 2/20 | 0.37 |
| ▸ | ELOB | Q15370 | 2/20 | 0.37 |
| ▸ | STAT6 | P42226 | 5/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25095633 | 0.88 | STAT6 (0.36) | VHLELOCELOBSTAT6ELANE | |
| SCHEMBL25757232 | 0.87 | STAT6 (0.36) | VHLELOCELOBSTAT6ELANE | |
| SCHEMBL24068380 | 0.87 | STAT6 (0.36) | VHLELOCELOBSTAT6ELANE | |
| SCHEMBL24068291 | 0.86 | VHL (0.37) | VHLELOCELOBELANECYP3A4 | |
| SCHEMBL26749959 | 0.83 | STAT6 (0.38) | STAT6ELANEPOLB | |
| SCHEMBL25906673 | 0.81 | EPHX1 (0.37) | KDM4E | |
| SCHEMBL12811967 | 0.79 | STAT6 (0.38) | STAT6ELANECYP3A4 | |
| SCHEMBL24068280 | 0.78 | VHL (0.35) | VHLELOCELOBSTAT6ELANE | |
| SCHEMBL21696763 | 0.78 | STAT6 (0.43) | STAT6ELANEHCRTR2 | |
| SCHEMBL25885362 | 0.78 | STAT6 (0.43) | STAT6ELANEHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | VHL 2117/4885ELOC 1508/4885ELOB 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.